The ASCO Post Podcast

Latest Episodes:

BEACON CRC: Patient-Reported Quality of Life Results Feb 06, 2020

Show notes

This week, we’ll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.

Coverage of stories discussed this week on ascopost.com:

2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC

2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test

News From the Gastrointestinal Cancers Symposium Jan 30, 2020

Show notes

The 2020 Gastrointestinal Cancers Symposium took place last weekend, and today, we’ll take a deeper dive into findings in pancreatic cancer and colorectal cancer. We’ll also review the FDA approval of tazemetostat in epithelioid sarcoma.

Coverage of stories discussed this week on ascopost.com:

‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA -Mutated Advanced Pancreatic Cancer

FDA Approves Tazemetostat for Epithelioid Sarcoma

Elevations in Cancer Incidence Among Responders to the WTC Site After the September 11 Attacks Jan 24, 2020

Show notes

We’ll begin with a study that focused on elevations in cancer incidence among responders to the World Trade Center site after the September 11, 2001 terrorist attacks. We’ll then turn to an analysis evaluating the effect of proton pump inhibitor use on decreased cognitive functioning among breast cancer survivors. Lastly, we’ll look at a trial that compared detection and grading of prostate cancer with a novel artificial intelligence system vs seasoned experts.

Coverage of stories discussed this week on ascopost.com:

Cancer Incidence in World Trade Center Responders to the September 11 Attacks

Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?

Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer

Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes Jan 17, 2020

Show notes

We’ll start off this week by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes. Then, we’ll move to a study that’s been covered a lot in the news: does the use of powder in the genital area increase a woman’s chance of ovarian cancer? Finally, we’ll cover two recent approvals from the FDA, for patients with bladder cancer and gastrointestinal stromal tumors, respectively.

Coverage of stories discussed this week on ascopost.com:

Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes

Is There an Association Between Powder Use and Risk of Ovarian Cancer?

FDA Approves PD-1 Inhibitor for BCG-Unresponsive, High-Risk Non–Muscle Invasive Bladder Cancer

FDA Approves Avapritinib for the Treatment of PDGFRA -Mutated Gastrointestinal Stromal Tumor

Recent Approvals From the FDA Jan 10, 2020

Show notes

The FDA certainly had a busy December, and this week, we’ll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.

Coverage of stories discussed this week on ascopost.com:

FDA Approves Olaparib for Patients With Germline BRCA -Mutated Metastatic Pancreatic Cancer

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer

FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer

FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer

FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer

News From the San Antonio Breast Cancer Symposium Dec 19, 2019

Show notes

In this episode, we’ll cover three important presentations from the San Antonio Breast Cancer Symposium. The first reports results from the HER2CLIMB trial on tucatinib, capecitabine, and trastuzumab for patients with HER2-positive metastatic breast cancer; the second discusses phase II findings on the activity of a novel HER2-targeting antibody-drug conjugate in HER2-positive metastatic breast cancer; and the third focuses on a postoperative treatment regimen for hormone receptor–positive, HER2-negative primary breast cancer.

Plenary Presentations From the 2019 ASH Annual Meeting & Exposition Dec 13, 2019

Show notes

On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting & Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma.

Sequence of Therapies for Metastatic Castration-Resistant Prostate Cancer Dec 05, 2019

Show notes

We’ll start with a trial focused on the sequence of therapies for metastatic, castration-resistant prostate cancer. Then, we’ll move on to an abstract presented at a recent American Heart Association meeting about the link between increased cardiovascular disease risk and increased cancer risk. Lastly, we’ll give you an update about the latest step in the confirmation process for Dr. Stephen Hahn, the oncologist nominated to be the next FDA Commissioner.

Coverage of stories discussed this week on ascopost.com:

Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer

Cardiovascular Disease Risk May Be Associated With Cancer Risk

Reports From the ESMO Asia Congress 2019 Nov 27, 2019

Show notes

This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We’ll also discuss last week’s FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.

Coverage of stories discussed this week on ascopost.com:

ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma

ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer

FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis

Nivolumab Plus Bevacizumab for Relapsed Ovarian Cancer Nov 22, 2019

Show notes

According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we’ll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we’ll discuss two recent FDA drug approvals for patients with hematologic disorders.

Coverage of stories discussed this week on ascopost.com:

Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer

What Is the Best Palliation for End-Stage Lung Cancer?

FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma

FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected